Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin

Ertugliflozin, a sodium glucose cotransporter‐2 inhibitor, is approved in the United States for treatment of type 2 diabetes mellitus. A novel two‐period study design with (14)C microtracer dosing in each period was used to determine absolute oral bioavailability (F) and fraction absorbed (F(a)) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Raje, Sangeeta, Callegari, Ernesto, Sahasrabudhe, Vaishali, Vaz, Alfin, Shi, Haihong, Fluhler, Eric, Woolf, Eric J., Schildknegt, Klaas, Matschke, Kyle, Alvey, Christine, Zhou, Susan, Papadopoulos, Dimitris, Fountaine, Robert, Saur, Didier, Terra, Steven G., Stevens, Lloyd, Gaunt, Daniel, Cutler, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039199/
https://www.ncbi.nlm.nih.gov/pubmed/29575530
http://dx.doi.org/10.1111/cts.12549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039199/
https://www.ncbi.nlm.nih.gov/pubmed/29575530
http://dx.doi.org/10.1111/cts.12549

Ejemplares similares